DS
RARE icon

David Shaw’s Ultragenyx Pharmaceutical RARE Stock Holding History

David Shaw’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,200
Closed -$2.31M – 5173
2021
Q2 		$2.31M Hold
24,200
– – ﹤0.01% 2800
2021
Q1 		$2.75M Hold
24,200
– – ﹤0.01% 2309
2020
Q4 		$3.35M Buy
+24,200
New +$2.87M ﹤0.01% 2182
2016
Q1 		– Sell
-10,900
Closed -$1.22M – 3715
2015
Q4 		$1.22M Sell
10,900
-13,300
-55% -$1.33M ﹤0.01% 2511
2015
Q3 		$2.33M Buy
+24,200
New +$2.77M ﹤0.01% 1980

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

David Shaw's RARE Position: Q2 2026 in Review

David Shaw increased its Ultragenyx Pharmaceutical (RARE) stake by 37% in Q2 2026, buying an estimated $11.7M and bringing the position to 1,730,193 shares worth $57.8M. The position accounts for 0.03% of the portfolio, ranked #684.

David Shaw first reported a position in RARE in Q1 2015 and has held it in 37 quarters since. The position peaked at $99M in Q4 2020. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • David Shaw held 1,730,193 shares of Ultragenyx Pharmaceutical worth $57.8M as of Q2 2026.
  • David Shaw bought 469,175 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $11.7M.
  • Ultragenyx Pharmaceutical made up 0.03% of David Shaw's portfolio in Q2 2026, its #684 holding.
  • David Shaw first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 37 quarters since.
  • David Shaw's Ultragenyx Pharmaceutical position peaked at $99M in Q4 2020.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.